Business · 08/05/2009Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for NEUPRO TRANSDERMAL SYSTEM Patent Extension
Summary
The Food and Drug Administration has officially set a regulatory review period for the patent extension of NEUPRO TRANSDERMAL SYSTEM, a human drug product, in accordance with federal regulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →